NAUT — Nautilus Biotechnology Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Annual balance sheet for Nautilus Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	PROSPECTUS	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	76.7	346	184	173	130
Prepaid Expenses
Total Current Assets	77.7	349	187	177	133
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	6.21	31.9	32.6	36.9	32.3
Long Term Investments
Other Long Term Assets
Total Assets	85	398	350	306	243
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Total Current Liabilities	3.02	5.81	6.79	9.12	7.63
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	6.31	34.9	35.1	40.2	34
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	78.7	364	315	265	209
Total Liabilities & Shareholders' Equity	85	398	350	306	243
Total Common Shares Outstanding